Skip to content
value.today
Definium Therapeutics, Inc. logo

Definium Therapeutics, Inc.

DFTX
$5.2 Bmarket cap on Oct 29, 2026
Compare
World rank
#3,474
Revenue
—
For year ending December-2025
Net income
$-184 M
SEC filing
Employees
105
As of December 31, 2025
SEC filing

Definium Therapeutics, Inc. in brief

Definium Therapeutics, Inc. is a listed company in the Healthcare sector, based in New York, New York, USA. Its market value was $5.2 B on 29 October 2026, which makes it the 3,474th largest listed company in the world and the 1,031st largest in the USA on this site. It employs about 105 people. Its shares trade under the symbol DFTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Definium Therapeutics, Inc.

We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including DT120 (previously referred to as MM120), and DT402 (previously referred to as MM402), our lead product candidates.

From the company's annual report filed with the US SEC: read the report

Definium Therapeutics, Inc. timeline

2 events, 2020–2026
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2026
  4. ✎
    Renamed Definium Therapeutics, Inc.
    Formerly Mind Medicine (MindMed) Inc..

Events of Definium Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1.4 B$2.8 B$4.2 B$5.6 B

World rank over time

▲ up 282 places since 2026
2026-10-14: #3764#3,76420262026-10-29: #3482#3,4822026

Rank in USA: #1,097 (Oct 2026) · #1,032 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
15.7×
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-55.3%
Liabilities / assets
24.5%
Net debt
$-217M
Profit per employee
$-1.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-34M—FY20Fiscal year ending Dec 2021: revenue —, net income $-93M—FY21Fiscal year ending Dec 2022: revenue —, net income $-57M—FY22Fiscal year ending Dec 2023: revenue —, net income $-96M—FY23Fiscal year ending Dec 2024: revenue —, net income $-109M—FY24Fiscal year ending Dec 2025: revenue —, net income $-184M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-166M$-184M—
Dec 2024——$-104M$-109M—
Dec 2023——$-94M$-96M—
Dec 2022——$-66M$-57M—
Dec 2021——$-94M$-93M—
Dec 2020——$-33M$-34M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-132M——$-2.06—
Dec 2024$-79M——$-1.54—
Dec 2023$-64M——$-2.44—
Dec 2022$-50M——$-1.84—
Dec 2021$-46M——$-3.40—
Dec 2020$-24M——$-0.13—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-35M—Dec ’24Three months to Mar 2025: revenue —, net income $-23M—Mar ’25Three months to Jun 2025: revenue —, net income $-43M—Jun ’25Three months to Sep 2025: revenue —, net income $-67M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-50M—Dec ’25Three months to Mar 2026: revenue —, net income $-77M—Mar ’26Three months to Jun 2026: revenue —, net income $-159M—Jun ’26Three months to Sep 2026: revenue —, net income $-51M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-51M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Definium Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-166 M
Net income
$-184 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$440 M
Total liabilities
$108 M
Total equity
$332 M

As of December-2025

Top 100 institutional investors in Definium Therapeutics, Inc.#

As of Sep 30, 2026
354 institutions held 117.9 M shares (about 86.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 47.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Definium Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.11,772,595+539,761 (+4.81%)8.60%$448 MNov 13, 2026
2FMR LLC9,082,203+4,329,282 (+91.09%)6.63%$346 MNov 10, 2026
3Capital World Investors8,255,584+2,887,861 (+53.80%)6.03%$314 MNov 12, 2026
4Janus Henderson Group Ltd.7,196,316—5.26%$274 MNov 16, 2026
5Avoro Capital Advisors LLC7,050,000-138,888 (-1.93%)5.15%$268 MNov 16, 2026
6Driehaus Capital Management LLC6,788,022-57,254 (-0.84%)4.96%$258 MNov 16, 2026
7Price T Rowe Associates Inc /MD/4,366,200-285,832 (-6.14%)3.19%$166 MNov 16, 2026
8Wellington Management Group LLP3,671,887+722,153 (+24.48%)2.68%$140 MNov 16, 2026
9Geode Capital Management, LLC3,644,857+44 (0.00%)2.66%$139 MNov 6, 2026
10State Street Corp3,301,116+235,726 (+7.69%)2.41%$126 MNov 12, 2026
11Capital International Investors2,980,623+17,213 (+0.58%)2.18%$113 MNov 12, 2026
12Octagon Capital Advisors LP2,511,000-439,000 (-14.88%)1.83%$96 MNov 16, 2026
13Alliancebernstein L.P.1,938,303+135,016 (+7.49%)1.42%$74 MNov 16, 2026
14Goldman Sachs Group Inc1,935,743+134,891 (+7.49%)1.41%$74 MNov 16, 2026
15Vanguard Portfolio Management LLC1,655,506+7,080 (+0.43%)1.21%$63 MNov 13, 2026
16Vanguard Capital Management LLC1,618,507+132,053 (+8.88%)1.18%$62 MNov 13, 2026
17Adage Capital Partners GP, L.L.C.1,250,000+250,000 (+25.00%)0.91%$48 MNov 16, 2026
18Charles Schwab Investment Management Inc1,189,322+105,746 (+9.76%)0.87%$45 MNov 16, 2026
19Northern Trust Corp1,183,557+14,319 (+1.22%)0.86%$45 MNov 16, 2026
20Ameriprise Financial Inc1,080,929-67,434 (-5.87%)0.79%$41 MNov 16, 2026
21Woodline Partners LP1,003,797+156 (+0.02%)0.73%$38 MNov 16, 2026
22Deep Track Capital, LP1,000,000-1,750,000 (-63.64%)0.73%$38 MNov 16, 2026
23Lord, Abbett & Co. LLC958,635New0.70%$36 MNov 13, 2026
24UBS Group AG928,669+429,202 (+85.93%)0.68%$35 MNov 10, 2026
25Ensign Peak Advisors, Inc913,732+447,626 (+96.04%)0.67%$35 MNov 12, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Definium Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Bank of New York Mellon Corp850,275+73,004 (+9.39%)0.62%$32 MNov 5, 2026
27Vanguard Fiduciary Trust Co849,295+21,602 (+2.61%)0.62%$32 MNov 13, 2026
28Bamco Inc /ny/844,732+324,624 (+62.41%)0.62%$32 MNov 16, 2026
29Invesco Ltd.821,607+730,269 (+799.52%)0.60%$31 MNov 12, 2026
30Neuberger Berman Group LLC794,053+106,514 (+15.49%)0.58%$30 MNov 13, 2026
31Polar Capital Holdings Plc775,961-1,292 (-0.17%)0.57%$30 MNov 16, 2026
32AWM Investment Company, Inc.764,800-20,000 (-2.55%)0.56%$29 MNov 13, 2026
33Barclays PLC761,867+711,571 (+1414.77%)0.56%$29 MNov 6, 2026
34Commodore Capital LP700,000-1,300,000 (-65.00%)0.51%$27 MNov 16, 2026
35Nuveen, LLC685,539-419,775 (-37.98%)0.50%$26 MNov 10, 2026
36Morgan Stanley684,735+229,823 (+50.52%)0.50%$26 MNov 13, 2026
37Boxer Capital Management, LLC683,615-314,885 (-31.54%)0.50%$26 MNov 16, 2026
38Qube Research & Technologies Ltd668,876-14,025 (-2.05%)0.49%$25 MNov 13, 2026
39Eventide Asset Management, LLC662,459-47,541 (-6.70%)0.48%$25 MNov 13, 2026
40Franklin Templeton Inc580,361+94,142 (+19.36%)0.42%$22 MNov 12, 2026
41Balyasny Asset Management L.P.549,443-348,215 (-38.79%)0.40%$21 MNov 16, 2026
42Bank Of America Corp /de/518,512+353,937 (+215.06%)0.38%$20 MNov 16, 2026
43Candriam S.C.A.515,277-99,148 (-16.14%)0.38%$20 MNov 3, 2026
44Great Point Partners LLC508,735+83,735 (+19.70%)0.37%$19 MNov 16, 2026
45Integral Health Asset Management, LLC500,000-50,000 (-9.09%)0.37%$19 MNov 16, 2026
46Catalio Capital Management, LP497,964-64,708 (-11.50%)0.36%$19 MNov 16, 2026
47Marshall Wace, LLP491,029-807,917 (-62.20%)0.36%$19 MNov 13, 2026
48Seven Grand Managers, LLC475,000+250,000 (+111.11%)0.35%$18 MNov 16, 2026
49ArrowMark Colorado Holdings LLC469,831-94,238 (-16.71%)0.34%$18 MNov 16, 2026
50Orbimed Advisors LLC443,900+78,500 (+21.48%)0.32%$17 MNov 16, 2026
51Assetmark, Inc399,964+3,422 (+0.86%)0.29%$15 MOct 21, 2026
52Patient Square Capital LP385,000New0.28%$15 MNov 10, 2026
53Susquehanna International Group, LLP367,147+326,193 (+796.49%)0.27%$14 MNov 16, 2026
54Logos Global Management LP350,000+270,000 (+337.50%)0.26%$13 MNov 16, 2026
55Silverarc Capital Management, LLC345,946-54,054 (-13.51%)0.25%$13 MNov 12, 2026
56Squadron Capital Management LLC340,000+255,000 (+300.00%)0.25%$13 MNov 16, 2026
57Sofinnova Investments, Inc.339,018+83,115 (+32.48%)0.25%$13 MNov 16, 2026
58Jpmorgan Chase & Co337,191+71,236 (+26.78%)0.25%$13 MNov 12, 2026
59PFM Health Sciences, LP335,101+86,081 (+34.57%)0.24%$13 MNov 16, 2026
60Russell Investments Group, Ltd.331,702+178,225 (+116.12%)0.24%$13 MNov 6, 2026
61Royal Bank Of Canada312,693+212,630 (+212.50%)0.23%$12 MNov 16, 2026
62Tetragon Partners GP Ltd310,892+23,902 (+8.33%)0.23%$12 MNov 16, 2026
63Cormorant Asset Management, LP275,000-125,000 (-31.25%)0.20%$10 MNov 16, 2026
64Royce & Associates LP250,547+41,996 (+20.14%)0.18%$10 MNov 9, 2026
65UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC240,266+29,083 (+13.77%)0.18%$9 MNov 16, 2026
66Swiss National Bank228,100+6,900 (+3.12%)0.17%$9 MNov 12, 2026
67Fred Alger Management, LLC226,345+101,089 (+80.71%)0.17%$9 MNov 16, 2026
68Two Sigma Investments, LP225,938-695,880 (-75.49%)0.17%$9 MNov 16, 2026
69Keystone Investors Pte LTD221,080+125,980 (+132.47%)0.16%$8 MNov 16, 2026
70First Turn Management, LLC216,531New0.16%$8 MNov 16, 2026
71Schroder Investment Management Group209,694New0.15%$8 MNov 16, 2026
72SEB Asset Management AB208,2540 (0.00%)0.15%$8 MNov 4, 2026
73Aberdeen Group plc192,415+17,415 (+9.95%)0.14%$7 MNov 10, 2026
74AQR Capital Management LLC182,923+48,771 (+36.36%)0.13%$7 MNov 16, 2026
75HSBC Holdings PLC182,786+65,304 (+55.59%)0.13%$7 MNov 16, 2026
76Alps Advisors Inc178,006+67,618 (+61.25%)0.13%$7 MNov 3, 2026
77Superstring Capital Management LP176,561-11,721 (-6.23%)0.13%$7 MNov 16, 2026
78Voya Investment Management LLC166,443+71,277 (+74.90%)0.12%$6 MNov 10, 2026
79AdvisorShares Investments LLC161,608+40,227 (+33.14%)0.12%$6 MNov 9, 2026
80Rhumbline Advisers160,569+2,473 (+1.56%)0.12%$6 MNov 10, 2026
81D. E. Shaw & Co., Inc.159,305-156,105 (-49.49%)0.12%$6 MNov 16, 2026
82Rock Springs Capital Management LP154,188+11,001 (+7.68%)0.11%$6 MNov 16, 2026
83Moody Aldrich Partners LLC148,870+97,845 (+191.76%)0.11%$6 MOct 27, 2026
84Clearbridge Investments, LLC148,781New0.11%$6 MNov 12, 2026
85Deutsche Bank AG\144,657+1,710 (+1.20%)0.11%$6 MNov 6, 2026
86Tri Locum Partners LP144,406-18,590 (-11.41%)0.11%$5 MNov 16, 2026
87Peregrine Capital Management LLC142,129New0.10%$5 MNov 9, 2026
88Van Eck Associates Corp132,348New0.10%$5 MNov 13, 2026
89California State Teachers Retirement System130,576+2,230 (+1.74%)0.10%$5 MNov 13, 2026
90Atom Investors LP125,807+76,371 (+154.48%)0.09%$5 MNov 16, 2026
91VANGUARD ASSET MANAGEMENT, Ltd120,728+42,124 (+53.59%)0.09%$5 MNov 13, 2026
92TD Asset Management Inc118,060-91,400 (-43.64%)0.09%$4 MNov 13, 2026
93HighVista Strategies LLC109,086-133,798 (-55.09%)0.08%$4 MNov 13, 2026
94Seven Fleet Capital Management LP108,647-40,000 (-26.91%)0.08%$4 MNov 16, 2026
95Verition Fund Management LLC107,737New0.08%$4 MNov 13, 2026
96Nicholas Investment Partners, LP105,175New0.08%$4 MNov 16, 2026
97Manufacturers Life Insurance Company, The104,035-42,333 (-28.92%)0.08%$4 MNov 13, 2026
98Informed Momentum Co LLC103,484-17,444 (-14.43%)0.08%$4 MNov 16, 2026
99Data Collective IV GP, LLC100,3500 (0.00%)0.07%$4 MNov 16, 2026
100Brevan Howard Capital Management LP97,275-59,537 (-37.97%)0.07%$4 MNov 16, 2026

All 354 institutional investors, with who bought and sold →

Mutual funds holding Definium Therapeutics, Inc.#

213 funds in 2 countries hold shares worth $1.8 B (about 29.8% of the company). Since their previous reports 163 added shares and 42 sold, buying $1.0 B net. By country: USA 211 ($1.8 B), Sweden 2 ($11 M).
Mutual funds holding Definium Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc7.69 M$362 M5.6%0.38%newJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.35 M$157 M2.4%0.19%+39%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.49 M$70 M1.1%0.07%+36%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.42 M$62 M1.0%0.18%+46%Jul 31, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.1.29 M$61 M0.94%0.51%newJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors1.19 M$56 M0.87%0.36%+373%Jun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.1.14 M$54 M0.83%0.36%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors743,400$35 M0.54%0.38%+5.7%Jun 30, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc.728,490$34 M0.53%0.35%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC779,396$34 M0.57%0.39%−4.6%Jul 31, 2026
🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund710,241$33 M0.52%0.58%newJun 30, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC710,000$33 M0.52%1.9%+3.5%Jun 30, 2026
🇺🇸 Vanguard Health Care FundWellington Management Company LLP740,600$32 M0.54%0.08%newJul 31, 2026
🇺🇸 Driehaus Small Cap Growth FundDriehaus Capital Management LLC595,284$28 M0.43%1.7%+28%Jun 30, 2026
🇺🇸 Lord Abbett Developing Growth Fund IncLord, Abbett & Co. LLC538,017$23 M0.39%1.1%newJul 31, 2026
🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC528,300$23 M0.39%0.31%newJul 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.511,828$22 M0.37%0.10%−9.0%Jul 31, 2026
🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P.439,375$21 M0.32%0.66%newJun 30, 2026
🇺🇸 Fidelity Blue Chip Growth FundFidelity Management & Research Company LLC449,300$20 M0.33%0.02%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC409,890$18 M0.30%0.39%no changeJul 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC373,412$18 M0.27%0.30%+217%Jun 30, 2026
🇺🇸 Columbia Acorn FundColumbia Management Investment Advisers, LLC366,447$17 M0.27%0.62%−28%Jun 30, 2026
🇺🇸 AB Discovery Growth Fund, Inc.AllianceBernstein L.P.356,881$17 M0.26%0.58%newJun 30, 2026
🇺🇸 Baron Discovery FundBAMCO, Inc.356,396$17 M0.26%0.92%newJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC354,369$17 M0.26%0.15%+5956%Jun 30, 2026
🇺🇸 iShares U.S. Pharmaceuticals ETFBlackRock Fund Advisors336,035$16 M0.25%1.4%+22%Jun 30, 2026
🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc.348,339$15 M0.25%0.61%newJul 31, 2026
🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC341,580$15 M0.25%0.37%−25%Jul 31, 2026
🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC308,458$15 M0.23%2.4%−1.1%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.316,210$14 M0.23%0.18%+46%Jul 31, 2026
🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc.281,317$13 M0.21%3.1%−11%Jun 30, 2026
🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC303,300$13 M0.22%0.28%newJul 31, 2026
🇺🇸 Fidelity SAI Small-Mid Cap Momentum Index FundFidelity Management & Research Company LLC300,955$13 M0.22%0.31%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC509,162$12 M0.37%0.03%−9.2%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.505,777$12 M0.37%0.07%+8.5%May 31, 2026
🇺🇸 Meridian Growth FundArrowMark Colorado Holdings, LLC254,159$12 M0.19%2.2%−2.7%Jun 30, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.473,075$11 M0.35%0.05%−1.6%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC239,678$11 M0.18%0.19%+50%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC238,664$11 M0.17%<0.01%+95%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC257,424$11 M0.19%0.45%+13371%Jul 31, 2026
🇺🇸 JNL Multi-Manager Small Cap Growth FundJackson National Asset Management, LLC220,767$10 M0.16%0.41%+98%Jun 30, 2026
🇺🇸 SMALLCAP World FundCapital Research and Management Company209,315$10 M0.15%0.38%newJun 30, 2026
🇸🇪 SEB LäkemedelsfondSEB Funds AB208,254$10 M0.15%0.54%newJun 30, 2026
🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I193,657$9 M0.14%1.1%−12%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC183,332$9 M0.13%0.38%+567%Jun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors155,099$7 M0.11%<0.01%+2.5%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC166,814$7 M0.12%0.18%+42%Jul 31, 2026
🇺🇸 Small-Cap Growth PortfolioPacific Life Fund Advisors LLC151,618$7 M0.11%1.2%+48%Jun 30, 2026
🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP151,000$7 M0.11%3.0%+2.0%Jun 30, 2026
🇺🇸 Emerald Growth FundRBB Fund, Inc.161,989$7 M0.12%0.48%—Jul 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC161,200$7 M0.12%0.32%−37%Jul 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.144,089$7 M0.11%0.32%+11%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC139,659$7 M0.10%0.17%+38%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.241,171$6 M0.18%0.03%+0.2%May 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC121,945$6 M0.09%0.37%+422%Jun 30, 2026
🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC115,671$5 M0.08%2.0%no changeJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC120,090$5 M0.09%<0.01%+89%Jul 31, 2026
🇺🇸 Small Cap Growth Stock PortfolioMason Street Advisors, LLC97,500$5 M0.07%0.51%newJun 30, 2026
🇺🇸 Select Pharmaceuticals PortfolioFidelity Management & Research Company LLC188,000$5 M0.14%0.30%no changeMay 31, 2026
🇺🇸 Fidelity Blue Chip Growth ETFFidelity Management & Research Company LLC103,206$4 M0.08%0.06%newJul 31, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.95,455$4 M0.07%0.33%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC185,050$4 M0.14%<0.01%+1.8%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation89,800$4 M0.07%0.19%+48%Jun 30, 2026
🇺🇸 Fidelity Blue Chip Growth K6 FundFidelity Management & Research Company LLC93,300$4 M0.07%0.02%newJul 31, 2026
🇺🇸 Nuveen ESG Small-Cap ETFNuveen Fund Advisors, LLC90,473$4 M0.07%0.31%+8.1%Jul 31, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.81,159$4 M0.06%0.51%newJun 30, 2026
🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC81,141$4 M0.06%0.34%newJun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.86,980$4 M0.06%0.33%newJul 31, 2026
🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P.79,711$4 M0.06%0.44%newJun 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.79,545$4 M0.06%0.54%newJun 30, 2026
🇺🇸 Adara Smaller Companies FundRBB Fund, Inc.150,124$4 M0.11%0.44%no changeMay 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC77,130$4 M0.06%0.19%+46%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC149,873$4 M0.11%<0.01%+2.5%May 31, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.76,035$4 M0.06%0.27%−5.7%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.79,611$3 M0.06%<0.01%+28%Jul 31, 2026
🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP72,500$3 M0.05%0.13%−16%Jun 30, 2026
🇺🇸 Hartford Small Cap Growth HLS FundHartford Funds Management Company, LLC72,200$3 M0.05%0.51%newJun 30, 2026
🇺🇸 Columbia Variable Portfolio - Acorn FundColumbia Management Investment Advisers, LLC71,158$3 M0.05%0.62%−28%Jun 30, 2026
🇺🇸 Column Small Cap Select FundTrust for Professional Managers136,454$3 M0.10%0.17%no changeMay 31, 2026
🇺🇸 Fidelity Series Blue Chip Growth FundFidelity Management & Research Company LLC74,400$3 M0.05%0.02%newJul 31, 2026
🇺🇸 Neuberger Small Cap Growth FundNeuberger Berman Investment Advisers LLC133,760$3 M0.10%0.47%newMay 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.65,803$3 M0.05%0.19%+46%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth FundGoldman Sachs Asset Management, L.P.127,905$3 M0.09%0.67%+34%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC70,287$3 M0.05%<0.01%+39%Jul 31, 2026
🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series68,629$3 M0.05%0.36%newJul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC62,307$3 M0.05%0.18%+46%Jul 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.55,953$3 M0.04%0.16%−85%Jun 30, 2026
🇺🇸 Allspring Small Company Growth FundAllspring Funds Management, LLC57,703$3 M0.04%0.49%newJul 31, 2026
🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC56,500$2 M0.04%0.18%newJul 31, 2026
🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc.51,914$2 M0.04%0.34%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Value FundGoldman Sachs Asset Management, L.P.97,359$2 M0.07%0.25%newMay 31, 2026
🇺🇸 Nuveen Small Cap Growth Opportunities FundNuveen Fund Advisors, LLC52,699$2 M0.04%0.87%newJul 31, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC52,257$2 M0.04%0.07%+41%Jul 31, 2026
🇺🇸 Variable Portfolio - Partners Small Cap Growth FundColumbia Management Investment Advisers, LLC46,031$2 M0.03%0.57%+22%Jun 30, 2026
🇺🇸 The Hartford Healthcare FundHartford Funds Management Company, LLC49,500$2 M0.04%0.28%newJul 31, 2026
🇺🇸 The Hartford Small Company FundHartford Funds Management Company, LLC48,700$2 M0.04%0.31%newJul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.86,461$2 M0.06%0.11%+44%May 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC47,936$2 M0.04%0.08%+39%Jul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC43,003$2 M0.03%0.19%+39%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC81,265$2 M0.06%0.03%newMay 29, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Definium Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$7.0 M
17 sales, 5 insiders
Net, 12 months
-$7.0 M
open market only
Insiders on file
18
since
$27 K-$3.0 M$0Dec 2023: bought $0 (0 trades), sold $93 K (3 trades)Dec 23Mar 2024: bought $0 (0 trades), sold $219 K (2 trades)Jun 2024: bought $0 (0 trades), sold $292 K (3 trades)JunAug 2024: bought $27 K (3 trades), sold $0 (0 trades)Sep 2024: bought $0 (0 trades), sold $200 K (4 trades)SepDec 2024: bought $18 K (1 trades), sold $242 K (4 trades)Mar 2025: bought $0 (0 trades), sold $249 K (4 trades)MarJun 2025: bought $0 (0 trades), sold $312 K (3 trades)Sep 2025: bought $0 (0 trades), sold $437 K (3 trades)SepDec 2025: bought $0 (0 trades), sold $561 K (3 trades)Mar 2026: bought $0 (0 trades), sold $797 K (3 trades)MarJun 2026: bought $0 (0 trades), sold $2.6 M (5 trades)Sep 2026: bought $0 (0 trades), sold $3.0 M (6 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Definium Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Robert BarrowChief Executive Officer, DirectorSell10b5-1 plan-31,550$36.57$1.2 M2.21 MForm 4
filed Daniel KarlinChief Medical Officer, DirectorSell10b5-1 plan-10,853$36.57$397 K792,846Form 4
filed Mark SullivanChief Legal OfficerSell10b5-1 plan-14,051$36.57$514 K494,228Form 4
filed Brandi RobertsChief Financial OfficerSell10b5-1 plan-3,377$36.57$123 K394,528Form 4
filed Matthew T. WileyChief Commercial OfficerSell10b5-1 plan-3,097$36.57$113 K359,036Form 4
filed Andreas KrebsDirectorOption exercise+1,629$35.52$58 K21,402Form 4
filed Carol A. ValloneDirectorOption exercise+1,086$35.52$39 K22,296Form 4
filed Brandi RobertsChief Financial OfficerGrant or award+125,000——397,905Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Definium Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
9.6 M
9.7% of shares · 5.77 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-09-14 10:55 UTC, code T3, resumed 11:30 UTC
  • 2026-08-12 10:55 UTC, code T3, resumed 11:30 UTC

Fails to deliver

  • : 504 shares at $38.10
  • : 9,851 shares at $37.08
  • : 45 shares at $35.68
  • : 4,643 shares at $35.67
  • : 265 shares at $32.10

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Definium Therapeutics, Inc. scorecard#

Passes 3 of the 14 checks that could be worked out: strongest in financial health (3 of 5), weakest in valuation (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median15.7×Price to book 15.7× against Healthcare's median of 3.1×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.06 vs -1.54Diluted EPS -2.06 in fiscal 2025 against -1.54 the year before (report's currency).
    • ✗Net income higher than five years earlier-$184 M-$184 M in fiscal 2025 against -$34 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$184 MNet income -$184 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-64.1%-64.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.29 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.12 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $217 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-30.4×Operating income -30.4 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year26.8%Diluted shares up 26.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Definium Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Definium Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development1186552363519
General and administrative493942305914
Operating expenses16610494669433
Operating income−166−104−94−66−94−33
Interest and finance income11125.6———
Interest expense and finance costs5.52.30.9r———
Net interest income——4.71.5−0.4−0.2
Other non-operating income (expense)−17−4.8−1.99.5−0.3−0.9
Income before tax−184−109−96−57−94−34
Income tax0———−1.2—
Net income including minority interests−184−109−96−57−93−34
Net income attributable to shareholders−184−109−96−57−93−34
Earnings per share, basic-2.06-1.54-2.44-1.84-3.40r-0.13
Earnings per share, diluted-2.06-1.54-2.44-1.84-3.40r-0.13
Shares, weighted average (basic)8970393127—
Shares, weighted average (diluted)8970393127r266
Balance sheet
Cash and cash equivalents25827410014213480
Short-term investments1540————
Other current assets7.77.94.23.93.71.4
Current assets41928210414613782
Goodwill20202020200
Other intangible assets—00.53.76.9—
Long-term investments—0————
Total assets44030212517016482
Accounts payable5.32.04.12.14.22.0
Current liabilities67393218103.0
Long-term debt412214———
Total liabilities108614619125.7
Retained earnings−583−399−290−194−138−45
Shareholders' equity3322417815115276
Total liabilities and equity44030212517016482
Shares outstanding9975413828r—
Cash-flow statement
Share-based compensation201715r14437.4
Cash from operating activities−132−79−64−50−46−24
Acquisitions, net of cash acquired————−0.3—
Cash from investing activities−1520——−0.3—
Shares issued01.07.5428272
Cash from financing activities26725322599997
Change in cash−16174−428.65373
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Definium Therapeutics, Inc. operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Definium Therapeutics, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Definium Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Definium Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 5 · Material agreement 3 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10

Definium Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changedResults announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Definium Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$75 MPrivate placement after listing$50 to $250 million2equitySEC
Aug 2023$7 MPrivate placement after listing$2 to $10 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Definium Therapeutics, Inc.#

$370 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$370 K
#706 among companies on value.today
Own lobbyists
Yes
files its own reports
Firms hired
0
in 2025
2026 so far
$320 K
  • Health Issues4 reports
Definium Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$320 K$320 K7
2025$370 K$370 K4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “MIND MEDICINE (MINDMED) INC.”, “​Definium Therapeutics (fka MIND MEDICINE (MINDMED) INC.)” and “Definium Therapeutics (fka MIND MEDICINE (MINDMED) INC.)”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Discuss Definium Therapeutics, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 9 November 2026automatic update · Nov 9, 2026

    Definium Therapeutics, Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $51 million.

  • Mutual funds: 213 funds hold $1.8 billionautomatic update · Jul 31, 2026

    213 mutual funds in 2 countries hold shares of Definium Therapeutics, Inc. worth $1.8 billion, about 29.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 163 funds added shares and 42 sold; on balance they bought $1.0 billion. Share splits are not counted as trading.

How Definium Therapeutics, Inc. compares in Healthcare

  • Market cap$5.2 B · higher than 86% of 2,013
  • Price / book15.7× · lower than 8% of 1,245
CompanyMarket capP/ENet marginRev. growth
Definium Therapeutics, Inc.🇺🇸$5.2 B———
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikidata, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Definium Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Definium Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Definium Therapeutics, Inc.? Suggest a correction